trending Market Intelligence /marketintelligence/en/news-insights/trending/ueodojwntd7hdtyfb1kclw2 content esgSubNav
In This List

Roche scores in cancer trial; Americans say drugmakers more influential than NRA


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Roche scores in cancer trial; Americans say drugmakers more influential than NRA

Top news

* Swiss drugmaker Roche Holding AG said its cancer drug Tecentriq when taken with Avastin and chemotherapy helped certain lung cancer patients live longer in a late-stage trial.

* In a new poll from the nonpartisan, nonprofit Kaiser Family Foundation, 72% of responders said drug manufacturers held the most sway over lawmakers, versus 52% for the National Rifle Association.

On the policy front

* Republican Sens. Lamar Alexander of Tennessee and Susan Collins of Maine had tried, but failed, to get a measure into the $1.3 trillion omnibus spending bill that would have temporarily restored the ACA's cost-sharing reduction subsidies — funds Trump ended in October 2017 — and provided $10 billion per year over three years in federal reinsurance.

* The U.S. Food and Drug Administration issued a policy document aiming to limit the number of drugs that can be used by outsourcing facilities to create new medicinal combinations by preparing a list of drug ingredients that have a clinical use.

M&A and capital markets

* Announced private equity and venture capital U.S. healthcare deals reached an all-time high in terms of the number of deals in 2017, with 128 deals valued at approximately $14.2 billion announced last year, S&P Global Market Intelligence data shows.

SNL Image

Drug and product pipeline

* Biohaven Pharmaceutical Holding Co. Ltd.'s anti-migraine drug, rimegepant, met the main goals in two late-stage clinical trials. The medicine was better than placebo at getting rid of pain and "most bothersome" migraine-associated symptoms in patients two hours after taking the first dose, results from the two studies showed.

* U.K.-based Verona Pharma plc said its RPL554 drug significantly improved the lung function in a phase 2b trial among patients with a breathing disorder known as chronic obstructive pulmonary disease.

* Protagonist Therapeutics Inc. said it will abandon a phase 2b study of its potential ulcerative colitis therapy, PTG-100, after an interim analysis deemed the study futile. Ulcerative colitis is an inflammatory bowel disease that causes inflammation of the digestive tract.

* Belgium-based TiGenix NV and Japan's Takeda Pharmaceutical Co. Ltd. received European Commission approval for Alofisel to treat conditions associated with Crohn's disease — an inflammatory bowel disease that affects the lining of the digestive tract.

* The European Medicines Agency recommended approving six new medicines in March, including Amgen Inc. and Allergan PLC's Kanjinti, a biosimilar of Roche's breast cancer drug Herceptin.

* Pfizer Inc. said its Chantix smoking-cessation treatment failed to help adolescents kick the habit in a study required by regulators.

Operational activity

* Chinese pharmaceutical distributor Sinopharm Group Co. Ltd. reported a 13.68% year-over-year rise in profit for the year ended Dec. 31, 2017, to 5.28 billion yuan.

* Pfizer will launch an over-the-counter version of its erectile dysfunction therapy, Viagra, in the U.K. to boost the falling sales of the off-patent drug, the Telegraph reported.

* AMAG Pharmaceuticals Inc. and Swiss drugmaker Novartis AG's Sandoz Inc. unit agreed to settle their patent dispute involving AMAG's anemia drug Feraheme.

* Indivior PLC said a U.S. court found that privately held Alvogen, Inc. did not violate three of the patents related to its opioid addiction therapy, Suboxone Film.

* Shire PLC said a U.S. district court ruled that Abhai LLC infringed on the Dublin-based drugmaker's patents related to the extended-release version of its attention deficit hyperactivity disorder drug Adderall.

Our features

* Celgene's neurology venture the latest strategy for revenue after Revlimid: After a string of setbacks that hit its stock price, the U.S. drugmaker is expanding its search for the next blockbuster medicine to new therapy areas.

SNL Image

Other features

* GlaxoSmithKline PLC CEO Emma Walmsley is transforming the British drugmaker's research-and-development operations after she replaced nearly half of the company's top 125 executives and reshaped its drug development unit by removing or reshuffling 400 scientists, The Wall Street Journal reported.

* Israel is planning to invest nearly 1 billion shekels to provide researchers and private companies access to the digital health records of its 9 million citizens as part of a so-called big data push to improve healthcare, Reuters reported.

* Reuters also has a report on Singapore's pharmaceutical manufacturing output, which is expected to recover following a dismal 2017.

* Guido Rasi, the head of the European Medicines Agency, spoke to the Financial Times about the regulator's upcoming physical relocation to Amsterdam as a result of Brexit.

The day ahead

Early morning futures indicators pointed to a higher opening for the U.S. market.

In Asia, the Hang Seng was up 0.79% to 30,548.77. The Nikkei 225 added 0.72% to 20,766.10.

In Europe as of midday, the FTSE 100 was up 0.45% to 6,952.81, and the Euronext 100 rose 0.27% to 999.02.

The Daily Dose is updated as of 6:30 a.m. ET.

S&P Global Market Intelligence provides links to external sites where these offer further, relevant information to our readers. While we ensure that such links are functional at the time of publication, we are not responsible in instances where those links are unavailable later. Some external links may require a subscription.